Form 4: Serina Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Jay Venkatesan, a director of Serina Therapeutics, acquired 40,000 stock options on February 12, 2025.
Summary
- On February 12, 2025, Jay Venkatesan, a director of Serina Therapeutics, acquired 40,000 stock options.
- The exercise price of these options is $4.60.
- The options vest in equal yearly installments over three years, starting on the first anniversary of the grant date, contingent upon continued service to the Issuer.
- The options expire on February 12, 2035.
Sentiment
Score: 5
Explanation: This is a neutral event. It simply reflects a director receiving stock options, which is a common form of compensation.
Industry Context
This is a standard SEC Form 4 filing, indicating a change in beneficial ownership of securities by a company insider. It's a routine part of corporate governance and transparency.
Stakeholder Impact
- The acquisition of stock options by a director could align their interests more closely with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/12/2025 | Date of the transaction: Jay Venkatesan acquired 40,000 stock options. |
| 02/12/2025 | Grant date of the stock options. |
| 02/12/2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.